Abstract: Introduction: Ocular lesions are the leading cause of morbidity in Behcet’s disease (BD). Many factors contribute to the loss of vision in BD, as uveitis, retinal vasculitis, and their secondary complications such as cataract, hemorrhage, vessel necrosis, neovascularization, optic atrophy, etc. The purpose of this study was to determine the impact of retinal vasculitis on the evaluation of ocular Behcet’s (OB) and its outcome after an early or late treatment. Materials & ...
Abstract: Behcet's Disease (BD) is classified among the Vasculitides. It is characterized by mucocutaneous and ophthalmologic manifestations and seen mostly in the Northern Hemisphere and in countries along the silk road. The characteristics of BD are presented here in a nation wide analysis of 3443 patients in Iran over a 21 year period. There was a slight male preponderance M.F ratio 1.4:1 (53.3% male/46.7% female). The mean age of onset was ...
Abstract: Introduction: We reported last year, during the ACR annual meeting, the result of different treatment modalities for ocular lesions of BD in 856 patients. We showed that pulse cyclophosphamide (PCP), low dose pulse cyclophosphamide (LDP), oral cyclophosphamide (OCP), weakly methotrexate (MTX), chloambucil (CHL), and cyclosparine A (CYA) had all the same efficacy. The percentage of the eyes aggravated (visual acuity) despite the treatment was: For PCP: 21%, LDP: 22%, OCP: ...
Abstract: Behcet's disease (BD) is not ran in Iran. The annual incidence is around 345 patients for a population of 60 millions. The male/female ratio is 1. 13. The mean age at the onset of the disease is 26.2+9.7 years (CI at 95%=0 .4). The prevalence of clinical signs were as follow: Mucous membrane lesions 96%+0.7 (oral aphthosis 95.7%, genital aphthosis 64%); skin lesions 74%±I.5 (pseudofolliculitis 66%, erythema nodosum 23%): ocular ...
Abstract: Considering that the majority of BD patients are from APLAR (Asia and Pacific League of Associations for Rheumatology) countries any diagnosis criteria for BD must have an adequate accuracy in these countries. The APLAR subcommittee for Behcet's Disease has set a prospective study to assess the accuracy of the existing diagnosis criteria. China, Iran, Japan, and Korea, the major countries with BD are participating to this study. The data from ...
Abstract: Introduction: Ocular lesions are the major cause of morbidity in Behcet's Disease. If not treated, they usually progress toward severe loss of vision or blindness. Cytotoxic drugs are the main therapeutic arsenal used for this condition. Materials & Methods: in an open, non randomized control study. Pulse Cyclophosphamida (PCP), low dose pulse cyclophosphamide (LDP), oral cyclophosphamide (OCP). weakly methotrexate (MTX), chlorambucil (CHL), and cyclosporine A (CYA) were used in a standard ...
Abstract: There is not yet an effective treatment for all lesions of Behcet's disease and for all patients with Behcet's disease. The highest morbidity is from the ocular lesions. The mortality, although rare, is due to neurological and pulmonary involvement. Thrombosis of the large veins and arteries, also rare, may lead to morbidity and mortality. In daily practice, the best treatment for muco cutaneous lesions is colchicine. Thalidomide may be efficient ...
Abstract: The aim of this study is to propose a scoring system to determine the activity of the eyes, and to evaluate our medications in the treatment of ocular inflammation and vasculitis in Behect's disease (BD). Eleven activity and 5 chronicity (constant) parameters are scored from zero to 4 to consider the condition of each eye in Oculo-Behcet's disease. Both parameters are considered in our therapeutic scoring. The activity variables are: Episcleritis and/or ...
Abstract: Introduction: There are several reports of good effects of Cyclosporine A (CsA) in the treatment of Behcet's disease (BD). We studied the long term effect of CsA in prospective open clinical trial on posterior uveitis (PU) and retinal vasculitis (RV) of BD. Materials & Methods: Twenty three patients with PU and/or RV diagnosed as BD (according to the Iran and to the Japan criteria) were selected. Initially CsA 5 mg/Kg/day orally ...
Abstract: Introduction: there are several reports of good effects of Cyclosporine A (Cs A) in the treatment of Behcet's disease (BD). We studied the long term effect, of A Cs A in a prospective open clinical trial on posterior uveitis (PU) and retinal vasculitis (RV) of BD. Materials & Methods: Twenty three patients with PU and / or RV diagnose as BD (according to the Iran and to the Japan criteria) ...